Lipid Nanoparticles Immunogenicity & Toxicity | December 6-8, 2022
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been […]
Biotech
Lipid Nanoparticles Development Summit Europe | 18th – 20th October, 2022
The LNP Development Europe Summit is the only European conference solely dedicated to LNP formulation and process development to enable seamless scale-up, keeping GMP compliance and manufacturing. Given the rapid developments in the […]
3rd TIGIT Axis Therapies Summit
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted […]
H1 Launches AI-Powered and Evidence-Based Interactions
What You Should Know: – H1, launches an update to its flagship product, HCP Universe, the daily resource for global medical affairs and medical science […]
Healthcare & Life Science M&A Activity Plummets 1H’22
What You Should Know: – The index of Healthcare & Life Science equities tracked by Stout was down 16.8% in Q2 2022, which was in […]
Traditional approaches to growth in biopharma are no longer sustainable
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no […]
The Benefits of Supporting Medical Information Teams with AI Agents
Richard Marcil, Chief Customer Officer at ConversationHEALTH Simon Johns, Director of Medical Information and Marketed Product Safety at IQVIA Life science organizations field a wide […]
Designing Digital Transformation for Life Sciences: Building Resiliency When Disruption is the New Normal
Dan UpDyke, Strategic Marketing Manager Life Sciences at Rockwell Automation The ability to navigate constant disruption is a prerequisite for success in today’s life science […]
Merck Digital Sciences Studio Launches to Support Biomedical Startups
What You Should Know: – Merck, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for […]
Data-Led Digital KOL Engagement
When creating engagement plans for individual Digital Key Opinion Leaders (DOLs), it’s best to look at a range of data-led metrics about each DOL to […]
SAE Media Group’s 2nd Annual Biosensors for Medical Wearables Conference
SAE Media Group’s 2nd Annual Biosensors for Medical Wearables *In collaboration with Medical Design Briefs* 24th – 25th October 2022 | Boston, MA, USA Sponsored […]
At BIO, French delegation highlights its plans for healthcare and biotech development [Sponsored]
The French delegation at BIO on June 13-16 has a compelling story to tell about biopharma and medtech growth and investment in France and the […]
Genomics England will move HQ to Canary Wharf’s new biocluster
Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by […]
PwC Report: 5 Key Actions for Pharma Companies to Drive Value Growth
What You Should Know: – A new PwC report offers insights into how pharma companies can translate game-changing science into greater returns. – Despite many major therapeutic advancements within […]
Phenomix Sciences Launches Obesity Biobanking Registry Studying Personalized Treatment Options Based on Genetics
What You Should Know: – Biotech company Phenomix Sciences launches its biobanking registry, marking the first obesity registry to study the impact of personalized treatment based on phenotyping. The […]
Genetics Startup Pleno Launches Out of Stealth with $15M
What You Should Know: – Pleno, a multi-omics startup, is emerging out of stealth with a $15M Pre-Series A financing and Greg Lucier as Chairman […]
Cerner Collaboration to Increase Access to Cancer Clinical Trials
What You Should Know: – Cerner, Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. – Together they […]
2nd Annual mRNA-Based Therapeutics Summit
Do you want to be part of the largest gathering of mRNA professionals? The 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. Expect exclusive data from […]
PING Conference 2022 – The Golden Age for Life Sciences Innovation
The PING Conference 2022 is back in person this year, with opportunities to network face-to-face with people from right across the life sciences ecosystem. We […]
SAE Media Group’s 3rd Annual Wearable Injectors and Connected Devices Conference
SAE Media Group’s 3rd Annual Wearable Injectors and Connected Devices Conference 10 – 11 October 2022 | London, UK http://www.wearable-injectors.co.uk/PharmaPhorum The Latest Innovations In Digital […]
Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines
What You Should Know: – Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding […]
3 Keys to Eliminating Data Breakdowns in Life Sciences
Sudish Mogul, Chief Technology Officer of Healthcare Triangle Across life sciences, experts boldly predict that data is the new currency—and that mobilizing data from clinical […]
Planning ahead while looking back: What the pandemic collectively taught us
As artificial intelligence becomes more focused and efficient, and the pharmaceutical and biotech industries consolidate to survive, it’s important to also reflect on what is […]
And then there were three; ex-Merck CEO Ken Frazier joins Eikon
The board of Eikon Therapeutics will soon look like Merck & Co’s a few years ago – after the big pharma’s former CEO Ken Frazier […]
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know: – VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series […]
Canary Wharf makes play to become UK life sciences hub
The organisation behind the iconic Canary Wharf development has said it plans to build one of the largest commercial laboratory facilities in Europe as part […]
Tempus Launches Pathology-Driven AI Platform
What You Should Know: – Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists […]
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient […]
Belgium’s Precirix raises €80m to fund radiopharma aspirations
Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development. […]
Biotechs pledge to sever Russian ties in solidarity with Ukraine
Hundreds of business leaders in the life sciences sector have added their names to an open letter that says they will cease all business dealings […]
Crisis in the U.S. Healthcare Workforce: Why It’s Time to introduce AI
Andrew Pucher, CEO of Dascena, Inc. One of the many acute challenges during the pandemic has been the departure of approximately 18% of the U.S. […]
Definitive Healthcare Acquires Analytical Wizards, Healthcare Analytics Platform
What You Should Know: – This week, Definite Healthcare announced the acquisition of Analytical Wizards, an advanced analytics company revolutionizing analytics in healthcare by combining […]
The Protein Degradation & Targeting Undruggables Congress
The 3rd Protein Degradation and Targeting Undruggables Summit is North America’s only in-person, industry-led conference covering clinical progress and commercial scale development of first-in-class degrader […]
C2i Genomics, Twist Bioscience Partner to Develop Whole-Genome Cancer Reference Materials
What You Should Know: – Today, Twist Bioscience and cancer genomics startup C2i Genomics announced a partnership to develop whole-genome cancer reference materials. – This […]
StartUPDATES: New developments from healthcare startups
Read about news from Equiva, DNA Script, Healthmine, Infermedica, and more.
Offshore warning as UK biotech investment rises sharply in 2021
2021 was a record year for investments in UK biotech companies, consolidating the country’s position as one of Europe’s top life science hubs and apparently […]
4th Treg Directed Therapies Summit 2022
Turbocharge the Development of Best-In-Class Treg-Directed Therapies, Maximising Stability and Function to Deliver Safe, Scalable and Efficacious Therapies Globally As Biopharma turn their focus to autoimmune drug […]
US vs EU: How can Europe translate home-grown innovation into biotech success?
We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United […]
Biotech R&D Platform Benchling Closes $100M at $6B Valuation
What You Should Know: Biotech R&D platform Benchling raises $100M at a $6B valuation, co-led by Franklin Templeton and Altimeter Capital to expand product development […]
OncoOne Entered into an Agreement with GenScript ProBio for the Manufacturing of Monoclonal Antibody Therapies Targeting oxMIF
Shots: The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF […]
Merck KGaA Collaborated with Burning Rock for Liquid-biopsy Based CDx Development
Shots: The companies collaborated for CDx development of tepotinib in mainland China. The CDx test is based on Burning Rock’s OncoCompass target which is a […]
Sotio Signs a Multiple Agreement with LegoChem Biosciences to Develop Novel Therapeutics for the Treatment of Solid Tumors
Shots: LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals […]
Entos Entered into an Agreement with BioMarin for Gene Therapies to Treat Genetic Diseases
Shots: Entos will use its Fusogenix nucleic acid delivery system to develop BioMarin products for multiple genetic diseases. BioMarin will be responsible for the preclinical […]
StartUPDATES: New developments from healthcare startups
Read news from Carrum Health, Healthmine, 1upHealth, and more.
Secarna Signs Multiple Agreement with Achilles Therapeutics to Develop Optimized T cell Therapies
Shots: Secarna to receive an upfront along with an option exercise fees & is also eligible to receive development & commercial milestone along with royalties […]
Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
Shots: This agreement will expand Mustang’s pipeline of ex vivo lentiviral gene therapies for the treatment of SCID Lentiviral gene therapy is currently being evaluated […]
Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies
Shots: Dunad to receive $24M up front, equity investment, research funding & is eligible to receive ~$1.3B milestones along with royalties & will also be […]
Moderna Entered into a Research and Development Collaboration with Metagenomi to Develop In Vivo Gene Editing Therapeutics
Shots: Metagenomi to receive an up front, equity investment & is eligible to receive target option exercise fees in addition to development, regulatory, and commercial […]
Merck Entered into a WW Research Collaboration and License Agreement with Synthekine to Develop Novel Cytokine Therapeutics
Shots: Synthekine to receive up front along with an additional one-time payment, if selects a second target & will be eligible for ~$525M in development, […]
Takeda to Acquire GammaDelta to Advance the Development of Allogeneic γδT Cell Therapies for the Treatment of Solid Tumors
Shots: Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close […]
Selecta Collaborates with Ginkgo to Develop Therapeutic Enzymes for the Treatment of Orphan and Rare Diseases
Shots: Ginkgo is eligible to receive up front, R& D fees including milestones in the form of Selecta common stock, clinical & commercial milestones of […]
Vertex Collaborates with Mammoth Biosciences to Develop In Vivo Gene-Editing Therapies for Genetic Diseases
Shots: Mammoth to receive $41M up front, $650M as future payments based upon the achievement of prespecified research, development & commercial milestones across 2 programs […]
How are the European pharma and biotech sectors addressing strategic communications?
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna […]
Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease
Shots: Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on […]
Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics
Shots: F-star to receive $17.5M up front and is eligible to receive ~$1.35B as near-term fees & milestones along with royalties on net sales of […]
Sana Entered into an Agreement with Beam for Non-Exclusive Commercial Rights of its CRISPR Cas12b Nuclease System for Cell Therapy Programs
Shots: Beam to receive $50M up front & is eligible to receive a target option exercise fees, milestones upon achievement of development & sales milestones […]
Antios Enters into a Clinical Collaboration Agreement with Assembly Biosciences to Evaluate ATI-2173 and Vebicorvir for Chronic Hepatitis B Virus Infection
Shots: The companies collaborated to evaluate the safety, PK & antiviral activity of ATI-2173, vebicorvir & TDF in an ongoing P-IIa ANTT201 trial in 10 […]
Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy
Shots: Spark to get exclusive, WW license to develop, manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program The […]
Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies
Shots: The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver […]
AbCellera Enters into a Collaboration and License Agreement with Salipro to Boost Therapeutic Antibodies
Shots: Salipro to receive an up front, research payments and is eligible for a downstream milestones for several targets The collaboration will allow AbCellera to […]
Amgen Signs a R&D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases
Shots: Neumora has received a $100M as an equity investment and obtains an exclusive global right to develop and commercialize Amgen programs targeting casein kinase 1 delta […]
Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases
Shots: Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones […]
Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders
Shots: Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development […]
Xencor Enter into an Exclusive WW License Agreement with Janssen to Develop and Commercialize Plamotamab and Xmab CD28 Bispecific Antibody for B-Cell Malignancies
Shots: Xencor to receive $100M up front, $25M as an equity investment, ~$1.18B in milestones along with royalties on net sales of products that emerge […]
Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures
Shots: The companies terminated their collaboration that centered around bintrafusp alfa as the drug failed to show potential in INTR@PID Lung 037 study as the […]
Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China
Shots: Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & […]
Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies
Shots: Intract to receive an up front, development & commercial milestone along with royalties on product sales. Bio-Thera gets global license to Intract’s Soteria & […]
Identifying KOLs in Growing and Emerging Markets
The process of discovering HCPs who are leading key opinion leaders (KOLs) in emerging and growing markets is not as straightforward as it is in […]
AstraZeneca Collaborates with VaxEquity to Develop and Commercialize Self-Amplifying RNA Therapeutics
Shots: VaxEquity can receive ~$195M in development, approval, and sales-based milestones along with royalties per program & is also eligible to receive an equity investment […]
Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections
Shots: The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza The preclinical […]
AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies
Shots: Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive […]
Novartis to Acquire Arctos to Boost its Optogenetics Portfolio to Treat Eye Diseases
Shots: The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology The acquisition marks the […]
Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases
Shots: Gubra to receive ~ $253.4M as up front, development, and commercialization milestones The collaboration will combine Gubra’s peptide drug discovery capabilities with Bayer’s expertise […]
Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU
Shots: Coave to receive $11.7M up front & equity investment, ~ $76.5M as clinical development, regulatory & commercial milestones along with royalties on net sales […]
Clarus Signs an Exclusive WW License Agreement with McGill University to Develop and Commercialize its Technology for Rare Conditions Due to Coenzyme-Q10 Deficiencies
Shots: McGill to receive $350,000 up front, $10.5M as development and regulatory milestone & is also eligible for ~$30M as a commercial milestone. Clarus will […]
AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies
Shots: AbCellera acquires TetraGenetics in an all-cash transaction that includes up front, milestones based on the achievement of technical milestones related to the development of […]
ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number […]
Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech and Medtech Companies
What You Should Know: – Lightstone Ventures today announced the closing of Lightstone Ventures III with $375M in capital commitments, to invest in early-stage companies […]
Rome Therapeutics raises $77m for junk DNA-targeting drugs
Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – […]
ONO and BMS Report Submission of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L Treatment of Unresectable Advanced or Recurrent ESCC in Japan
Shots: The application is based on P-III CheckMate -648 study evaluating Opdivo (3mg/kg, q2w, IV) + Yervoy (1mg/kg, q6w up to 24mos.) or Opdivo + […]
Everest Signs a License Agreement with Providence to Advance mRNA Vaccines
Shots: Providence to receive $100M up front for Providence’s PTX-COVID19-B, mRNA technology & other products, ~$300M upon achievement of milestones, $100M in profit-sharing along with […]
France’s biotech ecosystem is primed for growth – it’s time to feed it
After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman. […]
Boehringer Ingelheim Signs a Research Agreement with Twist to Discover Therapeutic Antibodies Against Multiple Targets
Shots: Twist to receive an up front for each program and $710M in clinical, regulatory, and commercial milestones for the multiple target discovery programs Boehringer […]
Eli Lilly Signs a License and Research Agreement with ProQR to Develop & Commercialize RNA Therapeutic for the Treatment of Liver and Nervous System Disorders
Shots: ProQR to receive $20M up front, $30M as an equity investment & is also eligible to receive ~$1.25B as development, regulatory, and commercialization milestones […]
Biotech Insight podcast: Overcoming planning challenges in oncology
The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular […]
16th Park Annual by Sahlgrenska Science Park
Nordic Health Innovation: From realisation to business A virtual life science event with thought-provoking presentations, unexpected angles, future trends and pioneering ideas. The Nordic region […]
Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies
Shots: Adaptimmune to receive $150M up front, $150M as additional payments over 5yrs., $3B+ as research, development, regulatory & commercial milestones along with royalties across […]
NeuExcell Signs a Research Agreement with Spark to Develop a Novel Gene Therapy for Huntington’s Disease
Shots: NeuExcell is eligible to receive $190M up front, license fees, R&D, and sales milestones along with royalties Spark gets the option to license the […]
BMS Exercised Its Option to License Evotec’s EVT8683 for the Treatment of Neurodegenerative Disease
Shots: Evotec receives $20M as an option fee & is eligible to receive ~$250M as milestones along with royalties. BMS will be responsible for further […]
Novartis Signs an Agreement with NHS to Commercialize Leqvio (inclisiran) for the Treatment of Cardiovascular Disease
Shots: The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England The NICE recommendation […]
Fresenius Medical Invests Additional $25M in Biotech Platform Humacyte
What You Should Know: Fresenius Medical Care (FMC) today announced its plans to invest an additional $25 million in clinical-stage biotechnology platform company Humacyte following the extension of […]
SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma
Shots: SpringWorks and Dana-Farber collaborated to evaluate nirogacestat with anti-B-cell maturation antigen (BCMA) agents in multiple preclinical multiple myeloma models SpringWorks will fund the work […]
BeiGene Signs a Clinical Trial Agreement with ImmixBio to Evaluate IMX-110 + Tislelizumab in Solid Tumors
Shots: ImmixBio to assess the safety, tolerability, and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors […]
Innovent Collaborates with Bolt to Develop Three Oncology Boltbody ISAC Programs
Shots: Bolt to receive $5M up front in cash & $10M as an equity investment. Both companies will receive milestones & royalties on the development […]
NovaRock Signs an Exclusive License Agreement with Flame to Co-Develop and Commercialize NBL-015
Shots: NovaRock to receive $7.5M up front and is eligible to receive ~$633M as development & sales milestones along with royalties on the sales of […]
Lilly Signs a License Agreement with Lycia to Develop Novel LYTAC Degraders
Shots: Lycia to receive $35M up front and is also eligible to receive an additional ~$1.6B upon the achievement of milestones along with royalties on […]
Vertex Expands its 2018 Agreement with Arbor to Develop Novel Ex Vivo Engineered Cell Therapies
Shots: Arbor to receive an up front in cash & is eligible to receive an additional ~$1.2B on achievement of milestones across up to 7 […]
Roche Signs a License Agreement with Shape to Advance AAV-based RNA Editing Technology for Neuroscience and Rare Disease
Shots: Shape is eligible to receive $3B+ including initial payment, development, regulatory, and sales milestone along with royalties on sales of therapies resulting from the […]
Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer
Shots: Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then […]
BMS Exercises its Option to Develop Exscientia’s AI-Designed Drug Candidate
Shots: Exscientia to receive $20M as an option exercise fee and is eligible for development milestones along with royalties on any product sales BMS has […]
5-Step Guide to Hiring AI Talent for Digital Health, Biotech & Life Sciences Companies
Michael Delisle, VP, Practice Leader for Digital Health at GattiHR Artificial Intelligence (AI) will disrupt healthcare’s destiny for good. Here are five steps digital health […]
Health Innovators: PureTech Health’s Daphne Zohar
In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. They […]
Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology
Shots: Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible […]
Incyte Signs a License Agreement with InnoCare to Develop and Commercialize Tafasitamab in Greater China
Shots: Incyte to receive $35M up front & is eligible to receive an additional ~$82.5M as development, regulatory & commercial milestones along with royalties. The […]
Seagen Signs an Exclusive WW License Agreement with RemeGen to Develop and Commercialize Disitamab Vedotin
Shots: RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of […]
AbbVie Receives $20M Milestone in its DUB Targets Collaboration with Mission to Treat Alzheimer and Parkinson Diseases
Shots: AbbVie selects two DUB targets to advance it to the next stage of drug discovery based on the results from in vitro & in […]
AbbVie Terminates its License Agreement with Molecular Partners for Abicipar Pegol
Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights […]
Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer
Shots: Appia Bio to receive $875M as an up front, equity investment, and milestone along with royalties. Kite will be responsible for the development, manufacturing, […]
AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis
Shots: AstraZeneca to receive up front & development, regulatory and commercial milestones along with royalties. The agreement will provide a novel compound into Sierra’s pipeline […]
Schrödinger Signs a R&D Collaboration with Zai Lab for Oncology Program Targeting DNA Damage Response
Shots: Schrödinger to receive up front to fund the share of research costs & is also eligible to receive ~$338M in pre/ clinical, regulatory & […]
Tachyon Collaborates with AbCellera to Develop Novel Antibody Therapies Targeting TGF-β Superfamily Member for Cancer
Shots: AbCellera to receive milestones and royalties on products that are derived from its Ab discovery platform. Additionally, AbCellera has the option to invest in […]
Marinus Signs an Agreement with Orion for the Commercialization of Ganaxolone in EU
Shots: Marinus to receive ~$30M up front & is eligible to receive ~$115M in R&D reimbursement milestone on achievement of clinical & commercialization milestones along […]
Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders
Shots: Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties, if […]
Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine
Shots: HilleVax gets an exclusive license for the development and commercialization rights of Takeda’s HIL-214 globally (Ex-Japan). Takeda will hold the commercialization rights of the […]
Astellas Signs a License Agreement with Minovia for Novel Mitochondrial Cell Therapy Programs
Shots: Minovia receives a $20M up front and is eligible to receive ~$420M per product in development, regulatory & commercial milestone for mitochondrial cell therapies […]
Alnylam Signs a License Agreement with PeptiDream to Develop and Commercialize Peptide-siRNA Conjugates for Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
Shots: PeptiDream to receive an upfront along with R&D funding and may eligible for ~$2.2B in development, regulatory, and commercial milestones upon specified achievement along […]
Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses
Shots: Kumquat to receive an ~ $70M in upfront and an equity investment in addition to ~$2B in milestone based on the achievement of definite […]
Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases
Shots: Aristea to receive $60M as up front and $10M as equity investment in Aristea’s Series B financing. Arena gets an exclusive option to acquire […]
AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases
Shots: The collaboration will extend in 2022 for an additional 3yrs. Calico will lead R&D until 2025 & will advance projects into P-IIa through 2030 […]
PeptiDream and Takeda Expand its Research and License Agreement to Develop Peptide Drug Conjugates Targeting CNS Diseases
Shots: As per expanded collaboration, PeptiDream to receive ~$3.5B as up front, preclinical, development, launch, and commercial milestones and is eligible to receive royalties on […]
BioNTech Plans to Initiate the Clinical Study of Malaria and Tuberculosis Vaccines in 2022
Shots: BioNTech unveils the plan to develop the first mRNA-based vaccine to prevent malaria with anticipated initiation of the clinical study by the end of […]
Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets
Shots: The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen Biocon will gain rights to […]
Denali Reports Results of DNL310 in P-I/II Study in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
Shots: Denali reports data from the P-I/II study evaluating DNL310 (qw, IV) for both CNS and peripheral MPS II. All patients received doses of DNL310 […]
AstraZeneca’s Vaxzevria Demonstrates Effectiveness After One Dose Against Beta/Gamma and Delta Variants of SARS-CoV-2 Virus
Shots: RWE data from CIRN with support from the Public Health Agency of Canada and the Canadian Institutes of Health Research demonstrated that one dose […]
ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Boehringer Ingelheim for CD8 ImmunoPET Technology
Shots: ImaginAb to receive license fees for providing ongoing technical, clinical, and regulatory support to facilitate the successful implementation of its CD8 ImmunoPET technology Following […]
Synaffix Signs a License Agreement with ProfoundBio for ADC Technologies
Shots: Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s […]
Relmada In-Licenses Psilocybin Program from Arbormentis
Shots: Arbormentis to receive $51M upfront in cash and equity in addition to $150M as milestone related to pre-specified development and commercialization milestones along with […]
BioNTech Signs a Purchase Agreement to Acquire Kite’s Cell Therapy, R&D Platform and Manufacturing Facility in Gaithersburg, MD
Shots: Kite will receive a one-time upfront to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform, R&D & clinical manufacturing facility in Gaithersburg. The […]
AstraZeneca Signs an Exclusive WW License Agreement with Aridis for Suvratoxumab to Prevent Pneumonia
Shots: AstraZeneca to receive $11M up front in cash and Aridis common stock. & will also receive ~ $115M upon the achievement of development and […]
Merck’s Vaxneuvance (pneumococcal 15-valent conjugate vaccine) Receives the US FDA’s Approval for the Prevention of Invasive Pneumococcal Disease Caused by 15 Serotypes
Shots: The approval is based on seven P-II & III clinical studies involves assessing the safety, tolerability & immunogenicity of Vaxneuvance vs PCV13 in 7,438 […]
Eli Lilly Signs an Agreement with Banner Alzheimer’s Institute to Evaluate Donanemab in P-III TRAILBLAZER-ALZ 3 Trial for Alzheimer’s Disease
Shots: The collaboration is a part of the planned P-III TRAILBLAZER-ALZ 3 trial of donanemab vs PBO in patients with cognitive & functional decline related […]
StartUPDATES: New developments from healthcare startups
Read about new developments from HealthMine, TailorMed, Heru and Entos.
Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics to Correct RNA Expression
Shots: Skyhawk collaborated with Aragen for the development of small molecule therapeutics that correct RNA expression Under the collaboration, Skyhawk will get multiple discovery chemistry […]
Heat Biologics Signs a Research License Agreement with ProBioGen for Transposase System and Suspension HEK293 Cell Line
Shots: ProBioGen collaborates with Heat Biologics for both ProBioGen’s DirectedLuck Transposase System along with suspension HEK293 cell line The DirectedLuck Transposase is well-matched with additional […]
Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells
Shots: ExCellThera to receive up front, future contingent payments along with manufacturing and supply fees for the licensed molecules The collaboration validates the immense clinical […]
Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology
Shots: Bicycle receives $45M as up front and is eligible to receive development, regulatory and commercial milestones along with royalties for each program developed under […]
Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B
Shots: Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones Novo Nordisk acquires Prothena’s […]
Janssen Collaborates with Vor to Develop Engineered Hematopoietic Stem Cell Transplants with Bi-Specific Antibody Therapy to Treat AML
Shots: The collaboration will evaluate the combination of Vor’s eHSC transplant platform with Janssen’s bi-specific Abs for the treatment of AML The agreement stated that […]
Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS
Shots: Verge to receive ~$25M as up front, equity investment, and near-term payments in addition to ~$694M as milestone and royalties The collaboration will utilize […]
AstraZeneca Signs an Exclusive License Agreement with F-star Therapeutics for Novel STING Inhibitors
Shots: F-star is eligible to receive up front and near-term payments of ~$12M & will be eligible for ~$300M as development & sales milestone along […]
BeiGene Signs a Supply Agreement with PureTech for LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
Shots: The companies collaborated to evaluate BeiGene’s tislelizumab (anti-PD-1 immune checkpoint inhibitor) + PureTech’s LYT-200 (mAb targeting galectin-9) in patients with solid tumors associated with […]
Roche Enters into a Clinical Collaboration with Treos Bio for PolyPEPI1018 + atezolizumab in P-I/II Trial to Treat Late Stage Microsatellite Stable Metastatic Colorectal Cancer
Shots: The companies collaborated to evaluate Treos’ PolyPEPI1018 (Polypeptide cancer immunotherapy) + Roche’s atezolizumab (PD-L1-inhibitor) in P-I/II trial in patients with late-stage MSS mCRC which […]
Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan
Shots: The filing is based on the results from the P-III IMpower010 study assessing Tecentriq (1200mg, IV) vs BSC in 1,005 patients in a ratio […]
Sanofi Signs ~$1B Agreement with Eureka & MSK for their Multiple Myeloma Candidate
Shots: Eureka and MSK are eligible to receive up front and ~$1B as development, regulatory and sales milestone along with royalties on net sales. Sanofi […]
Make Mine Bioresorbable
By KIM BELLARD I learned a new word this week: bioresorbable. It means pretty much what you might infer — materials that can be broken […]
Roche Enter into a Collaboration with Mimetas to Develop Human Disease Models for Drug Development
Shots: Mimetas is eligible to receive up front and milestones while Roche will get an option to exclusively license specific disease models and assays for […]
Imugene HER2 vaccine hits target in stomach cancer trial
A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in […]
UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing
The UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – […]
Spero Therapeutics Enters into a License Agreement with Pfizer for SPR206 to Treat MDR Gram Negative Infections
Shots: Spero is eligible to receive $40M as an equity investment and ~$80M as development & sales milestones along with royalties on sales of SPR206 […]
Merck Amends Collaboration with NGM to Advance Novel Therapies for Retinal and CVM Diseases
Shots: NGM to receive ~ $120M as research & development funding through Mar’24, including ~$86M for the period from Apr’21 through Mar’22 & additional option […]
GSK and Alector Sign $2.2B Collaboration to Develop Therapies for Neurodegenerative Diseases
Shots: Alector to receive $700M as up front and is eligible to receive ~$1.5B as milestones. The companies collaborated to co-develop AL001 and AL101 for […]
Nestle and Seres Collaborate to Jointly Commercialize SER-109 for Recurrent Clostridioides difficile Infection
Shots: Seres to receive $175M up front, $125M upon the US FDA’s approval of SER-109 along with ~$225M as a commercial milestone. Seres will be […]
Pharma’s use of synthetic biology could deliver radical innovation
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
Pharma’s use of synthetic biology could deliver radical innovation
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
Health Tech, Part I: Where We Are Going, Not Just How Fast We Can Get There
By MIKE MAGEE What will be the lasting impact of the Covid 19 pandemic? We still don’t know the answer to that question in full. […]
Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem
Shots: Lineage to receive an upfront payment in cash and, if the option is exercised, Lineage will be eligible for additional payments, including event-specific payments, […]
BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma
Shots: The first patient has been dosed in a P-II cancer vaccine trial evaluating the efficacy, tolerability & safety of BNT111 + Libtayo in combination […]
StartUPDATES: New developments from healthcare startups
Read news from healthcare and life science companies including HealthMine, Zus Health, Sema4 and more.
Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies
Shots: Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in […]
Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA
Shots: The RELIEF study evaluating the efficacy & safety of VYEPTI (100mg, 30-minute IV infusion) vs PBO in a ratio (1:1) in 480 patients with […]
Cell Line Development and Characterization: An Ocean of Opportunities for Service Providers
The growing pipeline of monoclonal antibodies, vaccines, enzymes, biosimilars and other therapeutic proteins have created an ever- increasing demand for highly- productive and stable cell […]
Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies
Shots: Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally, it is eligible to receive […]
GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer
Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on […]
Vertex and CRISPR Therapeutics Present New Data of CTX001 from 22 Patients with TDT and SCD at EMA 2021
Shots: The ongoing two P-I/ II studies, CLIMB-Thal-111 & CLIMB-SCD-121 evaluating CTX001 in 45 patients with a follow-up of ~2yrs. after infusion aged 18-35yrs to […]
Antibody Purification: A Deeper Look into Service Providers Landscape
Over time, several innovative technologies have been developed to support the designing and manufacturing of various types of antibody products; however, the aforementioned processes are […]
Pharmaceutical Manufacturing and Packaging Congress 2021
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2021) will be held on the 28th – 29th of June, 2021 at the BGS online platform. CIOs and […]
Takeda Expands its License Agreement with Codexis to Discover Novel Gene Therapies for Fourth Rare Genetic Disorders
Shots: The companies expanded their license agreement for the research and development of an additional gene therapy for a lysosomal storage disorder. Takeda has exercised […]
BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies
Shots: Shoreline to receive $45M up front in cash and is eligible to receive R&D funding, milestones along with royalties, following the achievement of certain […]
Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China
Shots: The partnership will utilize Novogene’s molecular diagnostics capabilities to expand patient identification by NGS in China for supporting the development of Hummingbird’s HMBD-001 which […]
AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson’s Disease and Other Related Disorders
Shots: Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and […]
Immunocytokines – The Power of Fusion Proteins
Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World […]
StartUPDATES: New developmemts for healthcare startups
Read about new developments from Stellar Health, Paige, venBio, and more.
How Microsoft Teams streamlined cross-country forecasting for biotech pioneers.
J+D Forecasting has worked with one of Europe’s largest, leading biotechnology pioneers, helping to facilitate better, more collaborative forecasting for hundreds of colleagues across the continent. […]
Prostate Cancer Drug Development Summit
The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of […]
StartUPDATES: New developments from healthcare startups
Read about new developments from Blue Therapeutics, Docbot, Sema4, and Deep Lens.
Senti Bio Collaborates with BlueRock to Develop Gene Circuit Engineered Cell Therapies for Regenerative Medicine
Shots: BlueRock to get an option to license gene circuits emerging from the collaboration for cell therapy products in specific indications. If option exercises, the […]
BMS and Xencor Collaborate to Use Xtend XmAb Technology in SARS-CoV-2 Neutralizing mAb Combination for COVID-19
Shots: BMS to get non-exclusive access to Xencor’s Xtend Fc technology to extend the half-life of a novel Ab combination therapy that is intended to […]
Boehringer Ingelheim to Develop Dicerna’s GalXC RNAi Candidate for NASH
Shots: Boehringer Ingelheim has accepted a GalXC RNAi candidate (DCR-LIV2) for advancement under the existing agreement b/w the companies for the discovery and development of […]
Sarepta’s SRP-9001 Demonstrates Robust Expression and Safety Results in ENDEAVOR Study for DMD
Shots: Sarepta reported positive 12wks. expression & safety results from the first 11 participants enrolled in Study SRP-9001-103. The study uses commercially representative SRP-9001 Patients […]
BMS Signs an Exclusive Global License with Agenus for its Anti-TIGIT Bispecific Antibody Program
Shots: Agenus to receive a $200M as up front & ~$1.36B as development, regulatory and commercial milestones plus royalties on net sales of the therapies. […]
Key insights for a successful first-time product launch
Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning […]
Charles River to Acquire Vigene Biosciences for $292.5M
Shots: Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price, the transaction includes contingent additional […]
Biogen and Envisagenics Enter into a Collaboration for the Advancement of RNA Splicing Research to Treat Central Nervous System Diseases
Shots: Biogen will utilize Envisagenics’ SpliceCore, an AI- driven RNA splicing platform to understand the regulation of different RNA isoforms in CNS cell types and […]
Dr Reddy’s Acquires an Exclusive License for Pregene’s PRG1801 in India
Shots: Pregene to receive $5M upfront and milestone for the 1st indication and $7.5M milestone for subsequent indications and is also eligible to receive $150M […]
Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials
Shots: The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 […]
Lilly Signs a ~$1.25B Research Collaboration with MiNA Therapeutics to Develop saRNA Therapies
Shota: MiNA to receive $25M as up front and is eligible to receive $245M as milestones for each of five potential targets along with royalties […]
Biogen Collaborates with Capsigen to Discover Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
Shots: Capsigen to receive $15M up front and is eligible to receive up to ~$42M as research milestones and ~$1.25B as additional payments upon the […]
AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer
Shots: The P-III POSEIDON study involves assessing Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment […]
AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy
Shots: AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs […]
Sanofi Signs a Three-Year Collaboration with Stanford Medicine to Accelerate Immunology Research
Shots: Sanofi and Stanford Medicine collaborated to initiate three “deep-dive” research projects focusing on autoimmune diseases and inflammatory conditions The partners will organize a joint […]
New UK biotech Inspira uncloaks with deal to develop inhaled COVID therapy
UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled therapy for COVID-19 that could be ready […]
Exelixis Acquires GamaMabs’ Oncology Antibody Program to Expand its Biotherapeutics Portfolio
Shots: Exelixis to acquire GamaMabs’ AMHR2 Ab technology for $5M and additionally payment upon achieving certain milestones. Following the closing of the transaction, Exelixis will […]
Athenex to Acquire Kuur Therapeutics for ~$185M
Shots: Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole […]
Repertoire Collaborates with Yale University to Identify Novel Antigen and T- Cell Receptor for Multiple Sclerosis
Shots: Repertoire and Yale University collaborated to understand the immunological causes of MS by identifying the specificity of various subsets of T cells The focus […]
BioMarin Collaborates with Allen Institute to Develop Gene Therapies for Rare Brain Diseases
Shots: BioMarin will receive an exclusive license to each program for research, development, and commercialization of the gene therapies The collaboration will utilize Allen institute […]
LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies
Shots: LogicBio to receive $10M up front with ~$581M as option payment and milestones along with royalties. Canbridge to get an exclusive option to license […]
InveniAI Collaborates with Shionogi on AI-Based Drug Discovery
Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI […]
Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M
Shots: Pieris to receive $10M upfront and is eligible to receive $353M in development, regulatory, and commercial based milestones along with royalties on sales of […]
Biotech and medical device companies raise $913M in a five-IPO week
The five life sciences IPOs this week continues the steady march companies are making to the public markets this year. This week’s activity follows a […]
Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies
Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across […]
Serimmune CEO: Leveraging the functional antibody repertoire will transform healthcare
In response to emailed questions, the CEO and CTO talk about the immune intelligence startups’ Human Immunity Map — a growing database of immune interactions […]
Led by Sequoia, Benchling Raises $200M to Accelerate R&D Cloud Platform
– Today Benchling, the leading life and sciences R&D cloud, announced a $200M Series E raise led by Sequoia Capital Global Equities and joined by […]
Spark Therapeutics Signs an Option Agreement with Senti Bio to Develop Precision Gene Therapies
Shots: Senti Bio to receive up front and funding to support its research activities. If Spark exercises the option, Senti Bio will be eligible to […]
Cellino Biotech developing tech to help scale stem cell therapies
Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for […]
Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity
The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in […]
Sanofi licences in potential oral IL-17 drug from UK’s C4X Discovery
Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million). […]
Cancer Research UK spinout Achilles raises $175.5m in IPO
UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised […]
BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration
Shots: In the P-I SPICE study, the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing […]
Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies
Shots: Artios to receive $20M upfront in addition to near term research funding to support the collaboration and is eligible to receive $1.3B in discovery, […]
Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides
Shots: In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo […]
9th PREDiCT: Tumor Models Cell Therapy Summit
With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. There is a crucial need to progress […]
3rd Cell Engager Summit
With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, […]
Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases
Shots: The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources, financial contribution, and experience from both […]
Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications
Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize […]
Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star
Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration […]
Morehouse College, Verily Announces $575k Endowed Life Sciences Scholarship to Support STEM Careers
– Today, Verily announced a partnership with Morehouse College in Atlanta, GA, to establish an endowed award of $575,000 to fund a new Verily Scholars Program. – […]
GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19
Shots: The EUA submission is based on an interim analysis of the P-III COMET-ICE study assessing VIR-7831 vs PBO for the early treatment of COVID-19 […]
Aura raises $80m to develop its virus-like cancer drugs
US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that […]
Takeda Collaborates with Evotec on RNA Targeting Drug Development
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of […]
Meet our new Chair Deborah Keller
Deborah Keller is a dynamic woman who gives off an immediate sense of warmth and humor. The moment she joined our video chat, she began […]
Meet our new Chair Deborah Keller
Deborah Keller is a dynamic woman who gives off an immediate sense of warmth and humor. The moment she joined our video chat, she began […]
Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under […]
Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under […]
Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates
Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales […]
Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates
Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales […]
Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis
Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access […]
PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab
Shots: BioVectra to provide its integrated CDMO services for the manufacturing of API of bentracimab for use in PhaseBio’s ongoing global studies and global commercial […]
SMA Foundation Collaborates with PTC to Discover and Develop Regenerative Medicine
Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases […]
Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19
Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa […]
Exelixis Signs an Exclusive License Agreement with WuXi Biologics to Expand its Growing Oncology Biologics Pipeline
Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized […]
Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes
Shots: Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future Additionally, Biolojic […]
bene : studio Launches HealthTech Product Accelerator Starting April 1st
What You Should Know: – bene : studio, a San Francisco, CA-based global digital product consultancy, announced its non-equity, online HealthTech Product Accelerator, starting on […]
UK chancellor Sunak urged to boost pharma and biotech in budget
UK chancellor Rishi Sunak has been urged to recognise the leading role that pharma companies are playing in the economy in this week’s budget. Sunak […]
More healthcare startups go public through SPACs — but will they succeed?
More healthcare startups are choosing to go public through mergers with special-purpose acquisition companies— publicly-traded shell companies created with the purpose of taking a private […]
Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids
Shots: The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders The focus of this agreement […]
UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development
Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop […]
Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies
Shots: The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies Luminary gets a non-exclusive license for TcBuster and […]
Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan
Shots: Chugai gets exclusive development and commercializing rights for AT-527 in Japan Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to […]
Could CRISPR cure HIV? US biotech Excision raises $60m to find out
US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out […]
GSK Expand its 2020 Collaboration with Vir to Advance New Therapies for Influenza and Other Respiratory Viruses
Shots: Vir will receive ~$225M up front, $120M as an equity investment and $200M as regulatory milestones, ~300M as option payment and will be responsible […]
Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease
Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery […]
Novartis Report Results of Kesimpta (ofatumumab) Sensoready autoinjector pen for Multiple Sclerosis
Shots: The multicenter survey involves assessing Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses, with RMS who received a disease modifying […]
Guardant Health Launches Guardant Reveal Liquid Biopsy Test for Early-Stage Colorectal Cancer
Shots: The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor […]
Mega biotech Centessa beams up ex-Warp Speed science chief Slaoui
Operation Warp Speed’s former science chief Moncef Slaoui is to lead research at a new mega-biotech called Centessa, formed by the merger of 10 privately-held […]
Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease
Shots: The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with […]
Disgraced biotech investor Woodford plans revival as UK biotech booms
Disgraced investor Neil Woodford plans to start a new biotech investment firm as he seeks to capitalise on a booming UK life sciences industry and […]
Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies
Shots: Ensoma to receive $100M in up front & preclinical research payment, $10M in equity investment, and is eligible to receive $1.25B as development and […]
BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer
Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future […]
Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics
Shots: The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations The collaboration will […]
AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies
Shots: Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and […]
